Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Medical Device

Bruce Davis joins LeukoDx

This article was originally published in Clinica

  • News

Executive Summary

Point-of-care diagnostics company LeukoDx (Towson, Maryland) has appointed Bruce Davis chief scientific officer. Dr Davis is the founder and president of Trilium Diagnostics, which is developing diagnostics assays for clinical cytometry and lab haematology. LeukoDx has also licensed a patent and technology from Trilium regarding quantifying CD64. The latter's CD64 test kits are CE marked for sale in Europe, and awaiting US FDA approval. LeukoDx plans to make CD64 the first biomarker to be used in its disposable test cartridge for diagnosing and monitoring sepsis, which will run on its point-of-care flow cytometry platform. The company is also developing tests for detecting urinary tract infection, and monitoring HIV progression and treatment.

Table

View full table

Topics

Tags:
Medical Device
Latest Headlines

Rise In Class I Device Recalls A ‘Grave Concern,’ Says FDA’s Anne Reid

Discreet Gait Freezing Solution Brings Therapy With The Tap Of An Apple Watch

Shuren Says CDRH Is ‘Turning The Ship Around’ As Operations Return To Normal

EU: Good News For IVDs And For Future Transparency Of Medtech Compliance

See All
UsernamePublicRestriction

Register

MT045216

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By